VIDAS ®

High sensitive Troponin l

Delivering a diagnosis in only 2 hours
 Did you know?
Worldwide 16 million people die annually of cardiovascular diseases,
specifically heart attacks or stroke (1)
top 10
VIDAS ®

High sensitiveTroponin I
Chest pain is among the reasons to visit an emergency department (ED),
accounting for about 5% of all ED visits (2)
Expected prevalence of acute myocardial infarction (MI) in chest pain patients in the ED (3)
5-10% 15-20%
STEMI NSTEMI Deliver high performance
INTENDED USE:
Optimize the management of ACS Aid in the diagnosis of myocardial infarction.
19 CV
●

with high sensitivity troponins (4)

● Aid in the risk stratification of patients with
symptoms suggestive of ACS with respect to
relative risk of all-cause mortality and major
ng/L 7%
adverse cardiac events (MACE) consisting of MI and The 99th percentile
At the 99th
● New generation of highly sensitive troponin (cTn) Level of cTn revascularization, at 30 days. has been defined
assays allows earlier detection of acute MI, with at 19 ng/L percentile
Conventional
shortening of time window for serial measurement to
generations
3 hours. of cTn

Accelerate patient triage with

● cTn has become a continuous variable with accurate assays High-sensitivity
measurement below the 99th percentile as well as Onset of Conventional cTn assays

high diagnostic accuracy in only 2 hours

small absolute changes within one or two hours. This myocardial infarction cut-off
has enabled development of algorithms for reliable (10% CV)
rule-out and rule-in of acute MI within 2 hours.
99th percentile
PATIENTS WITH SUSPECTED NSTEMI(5)
Time
Normal levels Ischemia or Necrosis
Micro- AT PRESENTATION T0
T = 0 h necrosis T = 6 h
Measurement of VIDAS HsTnI

< 2 ng/L ≥ 2 ng/L < 100 ng/L ≥ 100 ng/L

RULE-OUT OBSERVATIONAL ZONE RULE-IN

AT 2 HOURS T2h
Re-test VIDAS HsTnI
T0 AND T2h ∆ T2h - T0
< 6 ng/L Others ≥ 10 ng/L

RULE-OUT OBSERVATIONAL ZONE RULE-IN

(54.6%) (29.6%) (15.8%)
Sensitivity 97.7% AMI prevalence Specificity 95.2%
NPV 99.4% 8.6% PPV 74.5%

DIAGNOSIS
● Mandatory tool, in addition to clinical
assessment and ECG, to make a definitive
diagnosis of acute MI.
● Serial measurement to differentiate acute
from chronic cardiac myocyte damage.
● Algorithm based on admission values and absolute changes within the first 2 hours.
RISK STRATIFICATION ● Delivers a diagnosis - safe rule-out and accurate rule-in - of acute MI (NSTEMI) in the vast
majority (70%) of suspected chest pain patients.
● Additional tool in risk stratification ● Shortens the time needed to triage chest pain patients in the ED (will obviate the need for
to guide therapeutic decision making. prolonged monitoring with frequent serial blood sampling).
ST – segment elevation myocardial infarction
Non – ST – segment elevation myocardial infarction
Acute Coronary Syndrome ∆: Difference in cTn concentration NPV: Negative Predictive Value PPV: Predictive Positive Value
 AVAILABLE ON VIDAS®
INSTRUMENTS:
VIDAS®, MINI VIDAS®
AND VIDAS® 3
belonging to bioMérieux, or one of its subsidiaries or one of its companies. Any other trademark is the property of its respective owner. VIDAS apparatus is a used, pending and/or registered designs belonging to bioMérieux or one of

VIDAS® offers your lab simplicity and productivity. It will enhance your workflow, allowing you to
01/18/ 9312992/008/GB/D / Document and/or pictures not legally binding. Modifications by bioMérieux can be made without prior notice / BIOMÉRIEUX, the blue logo and VIDAS are used, pending and/or registered trademarks

handle batch series while maintaining specific management of emergency tests.

CARDIAC PANEL VIDAS® High sensitive Troponin I

Reference number 415386
l High sensitive Troponin I
Tests / kit 60
l NT-proBNP2
Time to result 20 min
l Galectin-3
Sample type Serum, Plasma (Li Hep)
l CK-MB
Sample volume 200 µL
l Myoglobin
Units ng/L
l Digoxin
Reportable measuring range 1.5 – 40 000 ng/L
Limit of quantification (LoQ) 2.9-4.9 ng/L
Limit of detection (LoD) 1.3-3.2 ng/L
Limit of blank (LoB) 0.0-1.9 ng/L
its subsidiaries or one of its companies / bioMérieux S.A. RCS Lyon 673 620 399 / Printed in France / thera / RCS Lyon B 398 160 242

Precision (99th percentile for

19 ng/L ; CV = 7.0%
the global healthy population)
Calibrators & Controls frequency 28 days

REFERENCES
1. Lozano R, et al. Lancet.2012;380:2095-128.
2. Bandstein N, et al. J Am Coll Cardiol. 2014;63:2569-78.
3. Mueller C, et al. Eur Heart J. 2015 Aug 29. pii: ehv409.
4. Roffi M, et al. Eur Heart J. 2015 Aug 29. pii: ehv320.
5. Lindahl B, et al. Heart. 2017;103:125-131

bioMérieux S.A. • 69280 Marcy l’Etoile • France • Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90
www.biomerieux.com • www.biomerieux-diagnostics.com